

Type 2 Diabetes Mellitus [2016]: Bulletin #3

<https://marketpublishers.com/r/T87C00FB550EN.html>

Date: June 2017

Pages: 0

Price: US\$ 1,045.00 (Single User License)

ID: T87C00FB550EN

Abstracts

This edition presents key opinion leader (KOL) views on recent developments in the type 2 diabetes mellitus market. Topics covered include: AstraZeneca's announcement of positive top-line results from the Phase IIIb/IV EXSCEL study evaluating the effect of once-weekly Bydureon versus placebo in type-2 diabetics; the FDA's boxed warning on risks of foot amputations for Johnson & Johnson's canagliflozin (Invokana/Invokamet) based on data from the CANVAS and CANVAS-R trials; and EnteroMedics reporting of three-year data from its vBloc DM2 study in obese type 2 diabetics.

Business Questions

How do KOLs view the data for AstraZeneca's EXSCEL study for Bydureon?

Bydureon did not show superiority for cardiovascular end-point; will it have a role in type 2 diabetes treatment algorithm? If so where?

How do KOLs see Bydureon in relation to Trulicity and other GLP-1s?

How do KOLs see the FDA's boxed warning for canagliflozin?

How do KOLs rate Invokana and other SGLT-2 inhibitors?

What potential do KOLs think EnteroMedics vBloc implant device and what challenges do they foresee?

Will vBloc find a role in the treatment of diabetic patients?

I would like to order

Product name: Type 2 Diabetes Mellitus [2016]: Bulletin #3

Product link: <https://marketpublishers.com/r/T87C00FB550EN.html>

Price: US\$ 1,045.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T87C00FB550EN.html>